Deal-Making
Lilly boosts diabetes portfolio with Sigilon buy
Deal MakingLilly boosts diabetes portfolio with Sigilon buyLilly boosts diabetes portfolio with Sigilon buy
Eli Lilly will acquire all shares of Sigilon Therapeutics for $34.6 million to gain access to its cell therapies for diabetes.